Incyte : INCY

All Incyte Articles

136 Articles

Lee Jackson | Feb 21, 2015 at 9:15 AM EST

Insider Selling Remains Choppy as Stock Market Grinds Higher

In a trend that seems somewhat locked into place, insiders continue to sell stock, though as we have seen most…

Chris Lange | Jan 9, 2015 at 1:55 PM EST

Has Agenus Run Too Much?

Agenus, in conjunction with Incyte, announced a global license for the development and commercialization of Agenus's proprietary Retrocyte Display antibody…

Jon C. Ogg | Dec 1, 2014 at 2:10 PM EST

5 Critical Biotech Drug Dates and Events for December

At least five upcoming dates could be big days in December, for better or worse, for individual biotech stocks.

Jon C. Ogg | Oct 31, 2014 at 8:40 AM EDT

Top Analyst Upgrades and Downgrades: Aegerion, Avon, Atmel, LinkedIn, Ocwen, Visa and More

These are the top analyst upgrades and downgrades featured by 24/7 Wall St. for Friday, October 31, 2014.

Chris Lange | Sep 18, 2014 at 10:15 AM EDT

Analyst Sees Incyte Worth 70% More

Incyte has serious upside potential, but the inherent risk within it may be too much for some investors to bear.

Jon C. Ogg | Sep 17, 2014 at 8:15 AM EDT

Top Analyst Upgrades and Downgrades: AEP, BHP, GE, Incyte, 3M, Tyco, Under Armour and More

These are the top analyst upgrades, downgrades and initiations covered by 24/7 Wall St. for Wednesday, September 17, 2014.

Lee Jackson | Sep 8, 2014 at 9:10 AM EDT

SunTrust Robinson Humphrey Starts Coverage on 5 Top Biotech Stocks

SunTrust Robinson Humphrey opens up coverage of the biotech sector with four top biotech stocks to buy and one Neutral-rated…

Lee Jackson | Jul 9, 2014 at 8:40 AM EDT

UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings

In a new research report, UBS analysts are very positive on some top biotech stocks before second-quarter earnings numbers hit…

Trey Thoelcke | May 22, 2014 at 8:40 AM EDT

Three Companies That Want to Cure Pancreatic Cancer

A new research report from Cowen cautions that progress on a cure for pancreatic cancer is slow, but steady. Drugs…

Jon C. Ogg | May 16, 2014 at 8:30 AM EDT

Top Biotech Stocks for Cancer Cures From Cowen

ThinkstockThe conference season is starting to get into full swing, and for the top biotech stocks, that means an appearance…

Trey Thoelcke | Apr 29, 2014 at 8:40 AM EDT

Top Analyst Upgrades and Downgrades: Buffalo Wild Wings, Coca-Cola, DSW, Intuitive Surgical and More

Here are the top analyst upgrades, downgrades and initiations seen from Wall Street on Tuesday, April 29, 2014. They include…

Jon C. Ogg | Apr 23, 2014 at 8:50 AM EDT

UBS Top Stocks to Buy Working for Cancer Cures

In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are…

Trey Thoelcke | Apr 21, 2014 at 9:05 AM EDT

J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside

In a new research report, the J.P. Morgan health care team highlights their top names to buy after the sell-off…

Trey Thoelcke | Apr 3, 2014 at 8:30 AM EDT

Jefferies Biotech Stocks to Buy With Breakthrough Drug Innovations

New drug innovations are affecting the way that physicians treat such debilitating and deadly diseases as cancer. In a new…

Jon C. Ogg | Feb 26, 2014 at 8:15 AM EST

Top Analyst Upgrades and Downgrades: LinkedIn, Safeway, NII Holdings, Rangold, EP Energy and More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Wednesday, February 26, 1014.…

1 … 5 6 7 8 9 10

Incyte : INCY

All Incyte Articles

Insider Selling Remains Choppy as Stock Market Grinds Higher

Has Agenus Run Too Much?

5 Critical Biotech Drug Dates and Events for December

Top Analyst Upgrades and Downgrades: Aegerion, Avon, Atmel, LinkedIn, Ocwen, Visa and More

Analyst Sees Incyte Worth 70% More

Top Analyst Upgrades and Downgrades: AEP, BHP, GE, Incyte, 3M, Tyco, Under Armour and More

SunTrust Robinson Humphrey Starts Coverage on 5 Top Biotech Stocks

UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings

Three Companies That Want to Cure Pancreatic Cancer

Top Biotech Stocks for Cancer Cures From Cowen

Top Analyst Upgrades and Downgrades: Buffalo Wild Wings, Coca-Cola, DSW, Intuitive Surgical and More

UBS Top Stocks to Buy Working for Cancer Cures

J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside

Jefferies Biotech Stocks to Buy With Breakthrough Drug Innovations

Top Analyst Upgrades and Downgrades: LinkedIn, Safeway, NII Holdings, Rangold, EP Energy and More

Fed’s Rate Freeze Could Sting for Social Security Recipients

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

MISL Investors: Watch the FY27 Budget Bill Before the Next Rally

Fed’s Rate Freeze Could Sting for Social Security Recipients

Incyte : INCY

All Incyte Articles

Insider Selling Remains Choppy as Stock Market Grinds Higher

Has Agenus Run Too Much?

5 Critical Biotech Drug Dates and Events for December

Top Analyst Upgrades and Downgrades: Aegerion, Avon, Atmel, LinkedIn, Ocwen, Visa and More

Analyst Sees Incyte Worth 70% More

Top Analyst Upgrades and Downgrades: AEP, BHP, GE, Incyte, 3M, Tyco, Under Armour and More

SunTrust Robinson Humphrey Starts Coverage on 5 Top Biotech Stocks

UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings

Three Companies That Want to Cure Pancreatic Cancer

Top Biotech Stocks for Cancer Cures From Cowen

Top Analyst Upgrades and Downgrades: Buffalo Wild Wings, Coca-Cola, DSW, Intuitive Surgical and More

UBS Top Stocks to Buy Working for Cancer Cures

J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside

Jefferies Biotech Stocks to Buy With Breakthrough Drug Innovations

Top Analyst Upgrades and Downgrades: LinkedIn, Safeway, NII Holdings, Rangold, EP Energy and More

Fed’s Rate Freeze Could Sting for Social Security Recipients

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Featured Reads

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s